Navigation Links
For Moderate to Severe Psoriasis, Thought Leaders' Opinions and Clinical Data Indicate That Emerging Biologics That Target IL-17 Have the Potential to Offer Improvements in Efficacy and Safety Over Current Therapies

BURLINGTON, Mass., June 24, 2013 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that surveyed dermatologists in the United States and Europe agree that a drug's effect on psoriatic plaques at 12-16 weeks is one of the attributes that most influences their prescribing decisions in moderate to severe psoriasis. Clinical data and the opinions of interviewed thought leaders indicate that the emerging biologics with novel mechanisms of action that target IL-17 have the potential to offer improvements over sales-leading adalimumab (AbbVie/Eisai's Humira) on this attribute.

(Logo: )

The DecisionBase report entitled Which Clinical Attributes Will Most Effectively Position Emerging Agents Against the Market Leader, Adalimumab? also finds that surveyed U.S. and European dermatologists and U.S. managed care organization (MCO) pharmacy directors consider therapies with a lower risk of serious infections than current therapies to be one of the greatest unmet needs in moderate to severe psoriasis. Interviewed thought leaders do not believe any emerging therapy has yet demonstrated clear potential to fulfill this unmet need. However, they are optimistic that agents with more-targeted mechanisms of action, including the IL-17 inhibitors, may offer improved safety compared to those that target multiple molecules or molecules that affect multiple downstream pathways.

The findings also reveal that more MCO pharmacy directors are willing to grant favorable formulary status to therapies that offer improvements in safety compared to the number who would grant this status to agents with improvements in efficacy. However, for drugs that are priced at a premium to adalimumab, MCO pharmacy directors indicate that improvements in the risk of serious infections will need to be substantial to secure reimbursement.

"When asked about factors influencing their treatment decisions, surveyed U.S. and European dermatologists assigned a high weight to a therapy's effect on psoriatic plaques at 12-16 weeks. However, they did not identify this attribute as an area of high unmet need," said Decision Resources Analyst Laura Croal, Ph.D. "The current market contains several biologic therapies with high levels of plaque clearance at 12-16 weeks. Greater unmet need was indicated for improvements on serious infection rates and sustained response rates beyond one year. Drug developers who invest in pivotal trials that extend to 52 weeks and then follow patients through several years of treatment may be in a position to fulfill these remaining unmet needs and differentiate their therapies in this increasingly crowded market."

About Decision Resources
Decision Resources ( is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources Group company.

About Decision Resources Group
Decision Resources Group is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources Group at

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.


SOURCE Decision Resources
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Boehringer Ingelheim Presents First Data for Tiotropium in Adolescents with Moderate Persistent Asthma
2. Nektar Announces that FDA Grants Fast Track Designation to NKTR-181, a New Oral Opioid Analgesic Molecule, for the Treatment of Moderate to Severe Chronic Pain
3. Johnson & Johnson Announces Discontinuation of Phase 3 Development of Bapineuzumab Intravenous (IV) in Mild-to-Moderate Alzheimers Disease
4. Takeda Submits Marketing Authorisation Application for Vedolizumab in Moderately to Severely Active Ulcerative Colitis and Crohns Disease in the European Union
5. AG Mednet CEO Abraham Gutman to Moderate Disruptive Technologies Session at CenterWatch Forum on Optimizing Clinical Research Performance
6. Rheumatoid Arthritis Patients are Moderately to Highly Satisfied with Their Current Drug Therapy, Rating Conventional DMARDs Highest on Ease of Use and Cost
7. Five-Year SIMPONI Data Reported In Treatment Of Signs And Symptoms Of Moderately To Severely Active Rheumatoid Arthritis
8. Takeda Submits Biologics License Application for a New Investigational Drug Vedolizumab, in Moderately to Severely Active Crohns Disease and Ulcerative Colitis in the United States
9. New data about the safety and efficacy of linagliptin in adults with type 2 diabetes who have moderate to severe renal impairment presented at ADA
10. Albireo Receives Positive Opinion for Orphan Drug Designation for A4250 for Severe Liver Diseases
11. Lilly Supports Research to Determine What a Dogs Nose Knows About People with Diabetes and Severe Hypoglycemia
Post Your Comments:
(Date:11/26/2015)... DUBLIN , Nov. 26, 2015 ... the addition of the "2016 Future Horizons ... Monitoring (TDM) Market: Supplier Shares, Country Segment Forecasts, ... offering. --> ... comprehensive analysis of the Japanese therapeutic drug monitoring ...
(Date:11/26/2015)... , November 26, 2015 ... addition of the "2016 Future Horizons ... of Abuse Testing Market: Supplier Shares, Country ... report to their offering. --> ... the "2016 Future Horizons and Growth ...
(Date:11/26/2015)... 26, 2015 ... of the  "2016 Future Horizons and ... Drug Monitoring (TDM) Market: Supplier Shares, ... Opportunities"  report to their offering.  ... the addition of the  "2016 Future ...
Breaking Medicine Technology:
(Date:11/28/2015)... (PRWEB) , ... November 28, 2015 , ... Trying to ... has created the COUCH BUDDY. "I conceived of this design due to personal experience ... for couch users. It promotes relaxation and convenience, as well as increases support. It ...
(Date:11/27/2015)... ... ... There is only one major question facing all law firms in the ... has not been an easy question to answer. Especially when the senior partners and ... don’t share the same discipline around working long hours. , In addition to ...
(Date:11/27/2015)... Denver, CO (PRWEB) , ... November 27, 2015 , ... ... U.S. cities are not changing the way that they are handling security in light ... increasing police and security presence in an attempt to stop an attack from reaching ...
(Date:11/27/2015)... ... November 27, 2015 , ... An inventor, from ... dispense prescription medications at home, so he invented the patent-pending ELECTRONIC M.D. , ... prescription medications. In doing so, it could help to prevent potential overdose situations. ...
(Date:11/27/2015)... ... 2015 , ... The print component of “Supporting Our Caregivers” ... New York, Minneapolis, South Florida, with a circulation of approximately 250,000 copies and ... vast social media strategy and across a network of top news sites and ...
Breaking Medicine News(10 mins):